SWTX Common Stock Set for Nasdaq Removal per SEC Form 25

Rhea-AI Filing Summary

SpringWorks Therapeutics, Inc. (SWTX) has filed a Form 25 with the U.S. Securities and Exchange Commission. Nasdaq Stock Market LLC, acting as the filer, is removing the company’s common stock from listing and registration under Section 12(b) of the Securities Exchange Act of 1934. The form certifies that Nasdaq has complied with the procedural requirements of 17 CFR 240.12d2-2(b), which allows an exchange to strike a security from listing, and notes that the issuer has likewise satisfied the conditions for voluntary withdrawal under 17 CFR 240.12d2-2(c) if applicable.

The document contains no explanation for the delisting, nor does it provide financial statements or indicate any concurrent corporate action such as a merger, acquisition, or transfer to another trading venue. The filing was signed on 1 July 2025 by Tara Petta, AVP, on behalf of Nasdaq Stock Market LLC. Once effective—generally 10 days after filing—the company’s common stock will no longer be traded on Nasdaq, and its Section 12(b) registration will be withdrawn.

Positive

• None.

Negative

• Removal from Nasdaq listing and Section 12(b) registration eliminates primary market liquidity and could depress valuation until an alternative trading venue or corporate rationale is disclosed.

Insights

Equity Market Analyst

TL;DR – Nasdaq has filed Form 25 to delist SpringWorks’ common stock; absent context, loss of primary listing is a liquidity and valuation headwind.

The Form 25 confirms that SpringWorks Therapeutics’ common shares will be stricken from Nasdaq and deregistered under Section 12(b) of the Exchange Act. No justification—such as a completed merger, strategic go-private decision, or transfer to another exchange—is given. From a market-structure standpoint, delisting typically reduces trading liquidity, narrows analyst coverage, and can restrict institutional ownership. Although shares may trade OTC after deregistration, the move generally increases execution costs and widens bid-ask spreads. Because the filing does not disclose mitigating factors, investors should view the event as negative to neutral pending further clarification.

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-39044

Issuer:	SpringWorks Therapeutics, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	100 Washington Blvd
	Stamford	CONNECTICUT	06902
Telephone number:					(203) 815-9412

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

common stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2025-07-01	By	Tara Petta		AVP
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did SpringWorks Therapeutics (SWTX) file with the SEC?

The company filed a Form 25, indicating its common stock will be removed from Nasdaq listing and Section 12(b) registration.

Which security is affected by the Form 25 filing?

SpringWorks’ common stock is the class of securities subject to delisting and deregistration.

Which exchange initiated the delisting?

The Nasdaq Stock Market LLC filed the Form 25 and certified compliance with SEC Rule 12d2-2(b).

When was the Form 25 signed?

The document was signed on July 1, 2025 by Tara Petta, AVP of Nasdaq Stock Market LLC.

Does the filing state why SpringWorks is being delisted?

No. The Form 25 provides no explanation or underlying reason for the removal from listing.

How soon will the delisting become effective?

Under SEC rules, a Form 25 generally becomes effective 10 calendar days after filing, unless otherwise withdrawn.